Medicare Drug Pricing Negotiations: Assessing Constitutional Structural Limits

, , &
Journal of Law, Medicine and Ethics 51 (4):956-960 (2023)
  Copy   BIBTEX

Abstract

A series of structural constitutional arguments lodged in multiple cases against Centers for Medicare and Medicaid Services’ (CMS) authorities to negotiate prescription drug prices via the 2022 Inflation Reduction Act threaten the legitimacy of CMS program and federal agency powers.

Categories

Keywords

Reprint years

DOI

10.1017/jme.2024.12

Links

PhilArchive



    Upload a copy of this work     Papers currently archived: 91,503

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

My notes

Similar books and articles

Where Strategy and Ethics Converge: Pharmaceutical Industry Pricing Policy for Medicare Part D Beneficiaries.Edward R. Balotsky - 2009 - Journal of Business Ethics 84 (S1):75 - 88.
Coverage for high-cost specialty drugs for rheumatoid arthritis in medicare part D.J. Yazdany, R. A. Dudley, R. Chen, G. A. Lin & C. W. Tseng - unknown
The Constitutionality of Medicare Drug-Price Negotiation under the Takings Clause.Raj Bhargava, Nathan Brown, Amy Kapczynski, Aaron S. Kesselheim, Stephanie Y. Lim & Christopher J. Morten - 2023 - Journal of Law, Medicine and Ethics 51 (4):961-971.
Government Support of Meaningful Drug and Device Innovation: Pathways and Challenges.Aaron S. Kesselheim - 2023 - Journal of Law, Medicine and Ethics 51 (S2):7-15.
Just Medicare: The Role of Canadian Courts in Determining Health Care Rights and Access.Colleen M. Flood - 2005 - Journal of Law, Medicine and Ethics 33 (4):669-680.
Just Medicare: The Role of Canadian Courts in Determining Health Care Rights and Access.Colleen M. Flood - 2005 - Journal of Law, Medicine and Ethics 33 (4):669-680.
The Prescription Drug Pricing Moment: Using Public Health Analysis to Clarify the Fair Competition Debate on Prescription Drug Pricing and Consumer Welfare.Ann Marie Marciarille - 2017 - Journal of Law, Medicine and Ethics 45 (s1):45-49.
Perverse Incentives in the Medicare Prescription Drug Benefit.David McAdams & Michael Schwarz - 2007 - Inquiry: The Journal of Health Care Organization, Provision, and Financing 44 (2):157-166.
Low-income Medicare beneficiaries and their experiences with the part D prescription drug benefit.Noemi V. Rudolph & Melissa A. Montgomery - 2010 - Inquiry: The Journal of Health Care Organization, Provision, and Financing 47 (2):162-172.
Demand for a Medicare Prescription Drug Benefit: Exploring Consumer Preferences under a Managed Competition Framework.Richard R. Cline & David A. Mott - 2003 - Inquiry: The Journal of Health Care Organization, Provision, and Financing 40 (2):169-183.
Do Medicare Beneficiaries Living With HIV/AIDS Choose Prescription Drug Plans That Minimize Their Total Spending?Katherine A. Desmond, Thomas H. Rice & Arleen A. Leibowitz - 2017 - Inquiry: The Journal of Health Care Organization, Provision, and Financing 54:004695801773403.
Reflections on medicare.Theodore R. Marmor - 1988 - Journal of Medicine and Philosophy 13 (1):5-29.
Field notes.Daniel Callahan - 2011 - Hastings Center Report 41 (2):c2-c2.
An International Review of Health Technology Assessment Approaches to Prescription Drugs and Their Ethical Principles.Leah Z. Rand & Aaron S. Kesselheim - 2020 - Journal of Law, Medicine and Ethics 48 (3):583-594.
Executive Authority to Reform Health: Options and Limitations.Madhu Chugh - 2009 - Journal of Law, Medicine and Ethics 37 (s2):20-37.

Analytics

Added to PP
2024-03-15

Downloads
12 (#1,075,977)

6 months
12 (#207,528)

Historical graph of downloads
How can I increase my downloads?

Citations of this work

No citations found.

Add more citations

References found in this work

No references found.

Add more references